A meta-analysis found no significant differences in once-a-week glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 2 diabetes. The research covered 34 clinical trials that involved more than 20,000 patients.
A meta-analysis found no significant differences in once-a-week glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 2 diabetes. The research covered 34 clinical trials that involved more than 20,000 patients.
Share this Article
Recommended